Liqing Kang

1.7k total citations
68 papers, 944 citations indexed

About

Liqing Kang is a scholar working on Oncology, Molecular Biology and Electrical and Electronic Engineering. According to data from OpenAlex, Liqing Kang has authored 68 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Electrical and Electronic Engineering. Recurrent topics in Liqing Kang's work include CAR-T cell therapy research (62 papers), Virus-based gene therapy research (10 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Liqing Kang is often cited by papers focused on CAR-T cell therapy research (62 papers), Virus-based gene therapy research (10 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Liqing Kang collaborates with scholars based in China, United States and Taiwan. Liqing Kang's co-authors include Lei Yu, Nan Xu, Depei Wu, Xiaoyan Lou, Depei Wu, Zhiqiang Yan, Xiaowen Tang, Minghao Li, Changju Qu and Haiping Dai and has published in prestigious journals such as Advanced Materials, Blood and Scientific Reports.

In The Last Decade

Liqing Kang

60 papers receiving 932 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liqing Kang China 19 722 316 246 204 188 68 944
Sanfang Tu China 16 582 0.8× 297 0.9× 144 0.6× 154 0.8× 201 1.1× 52 858
Kai Rejeski Germany 19 753 1.0× 279 0.9× 138 0.6× 160 0.8× 137 0.7× 64 947
Lekha Mikkilineni United States 12 783 1.1× 400 1.3× 197 0.8× 157 0.8× 236 1.3× 26 980
Yongxian Hu China 21 1.1k 1.5× 475 1.5× 261 1.1× 324 1.6× 353 1.9× 119 1.4k
Farzana Nazimuddin United States 9 865 1.2× 213 0.7× 234 1.0× 262 1.3× 276 1.5× 11 958
Thomas J. Fountaine United States 10 596 0.8× 240 0.8× 202 0.8× 149 0.7× 193 1.0× 22 848
Reona Sakemura United States 13 717 1.0× 249 0.8× 261 1.1× 227 1.1× 261 1.4× 54 879
Mireya Paulina Velasquez United States 15 589 0.8× 218 0.7× 132 0.5× 156 0.8× 271 1.4× 42 783
Maria‐Luisa Schubert Germany 20 1.0k 1.4× 397 1.3× 291 1.2× 339 1.7× 335 1.8× 40 1.2k
Tatsunori Goto Japan 14 435 0.6× 216 0.7× 163 0.7× 146 0.7× 240 1.3× 48 723

Countries citing papers authored by Liqing Kang

Since Specialization
Citations

This map shows the geographic impact of Liqing Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqing Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqing Kang more than expected).

Fields of papers citing papers by Liqing Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liqing Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqing Kang. The network helps show where Liqing Kang may publish in the future.

Co-authorship network of co-authors of Liqing Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Liqing Kang. A scholar is included among the top collaborators of Liqing Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqing Kang. Liqing Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fu, Chengcheng, Lingzhi Yan, Zhi Yan, et al.. (2024). 5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma. Blood. 144(Supplement 1). 4766–4766.
3.
Xu, Nan‐Jie, Weiyang Liu, Han Zhao, et al.. (2024). PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. Journal for ImmunoTherapy of Cancer. 12(4). e008429–e008429. 23 indexed citations
4.
Li, Yangzi, Qingya Cui, Lingling Liu, et al.. (2024). Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion. Cellular Oncology. 47(5). 1649–1661. 4 indexed citations
5.
Li, Yangzi, Sining Liu, Qingya Cui, et al.. (2023). Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion. Blood. 142(Supplement 1). 6803–6803. 5 indexed citations
6.
He, Jiajie, Rui Zou, Liqing Kang, et al.. (2023). Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review. Frontiers in Oncology. 13. 1283194–1283194.
7.
Chen, Liyun, Wenjie Gong, Haixia Zhou, et al.. (2023). Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Advances. 7(17). 4913–4925. 8 indexed citations
8.
Sun, Lei, Jing Wang, Liqing Kang, et al.. (2022). Nanoengineered Neutrophils as a Cellular Sonosensitizer for Visual Sonodynamic Therapy of Malignant Tumors. Advanced Materials. 34(15). e2109969–e2109969. 62 indexed citations
9.
Liu, Rui, Qian Cheng, Liqing Kang, et al.. (2022). CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma. Human Gene Therapy. 33(5-6). 318–329. 17 indexed citations
10.
Wei, Zhenyu, Nan Xu, Liqing Kang, et al.. (2022). Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk. BMC Bioinformatics. 23(1). 373–373. 10 indexed citations
11.
Gu, Jingxian, Sining Liu, Wei Cui, et al.. (2022). Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. Frontiers in Immunology. 13. 858590–858590. 6 indexed citations
12.
Qu, Changju, Rui Zou, Peng Wang, et al.. (2022). Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. Frontiers in Immunology. 13. 969660–969660. 25 indexed citations
13.
Jia, Yujie, Jingwen Tan, Nan Xu, et al.. (2022). Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Therapy — Oncolytics. 24. 719–728. 19 indexed citations
14.
Zhang, Ying, Jiaqi Li, Xiaoyan Lou, et al.. (2021). A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Frontiers in Oncology. 11. 664421–664421. 35 indexed citations
15.
Kang, Liqing, Xiaowen Tang, Jian Zhang, et al.. (2020). Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Experimental Hematology and Oncology. 9(1). 11–11. 49 indexed citations
16.
Kang, Liqing, Xiaowen Tang, Nan Xu, et al.. (2019). shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 2621–2621. 2 indexed citations
17.
18.
Yan, Lingzhi, Jingjing Shang, Liqing Kang, et al.. (2017). Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study. Blood. 130. 506–506. 26 indexed citations
19.
Song, Yancheng, et al.. (2017). Scalp cluster acupuncture combined with constraint-induced movement therapy improves functional recovery after ischemic stroke. Zhonghua wuli yixue zazhi. 39(2). 117–121. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sanfang Tu Breakdown of academic impact, for papers by Kai Rejeski Breakdown of academic impact, for papers by Lekha Mikkilineni Breakdown of academic impact, for papers by Yongxian Hu Breakdown of academic impact, for papers by Farzana Nazimuddin Breakdown of academic impact, for papers by Thomas J. Fountaine Breakdown of academic impact, for papers by Reona Sakemura Breakdown of academic impact, for papers by Mireya Paulina Velasquez Breakdown of academic impact, for papers by Maria‐Luisa Schubert Breakdown of academic impact, for papers by Tatsunori Goto
Rankless by CCL
2026